Clinical Trial Update: The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD [Phase 3]

View source ↗

Summary

Phase 3 trial comparing umeclidinium/vilanterol to tiotropium in COPD over 24 weeks; results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Umeclidinium/Vilanterol (umeclidinium/vilanterol)
• tiotropium (tiotropium)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2014-06-05